Početna stranicaAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
11,15 $
Prije radnog vremena:(0,45 %)−0,050
11,10 $
Zatvoreno: 27. stu, 05:50:42 GMT -5 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
11,22 $
Dnevni raspon
10,95 $ - 11,33 $
Godišnji raspon
10,41 $ - 19,09 $
Tržišna kapitalizacija
1,12 mlr. USD
Prosječna količina
1,42 mil.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 50,02 mil. | 613,22 % |
Operativni troškovi | 44,20 mil. | 5,21 % |
Neto dohodak | −2,62 mil. | 92,76 % |
Neto profitabilnost | −5,25 | 98,98 % |
Zarada po dionici | −0,03 | 92,68 % |
EBITDA | 708,00 tis. | 102,05 % |
Efektivna porezna stopa | −3,47 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 65,81 mil. | −57,04 % |
Ukupna imovina | 158,25 mil. | −22,08 % |
Ukupne obveze | 83,59 mil. | −10,07 % |
Ukupni kapital | 74,66 mil. | — |
Dionice u optjecaju | 96,36 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 14,38 | — |
Povrat imovine | −0,52 % | — |
Povrat kapitala | −0,73 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −2,62 mil. | 92,76 % |
Gotovina od poslovanja | −6,89 mil. | 81,98 % |
Gotovina iz ulaganja | 4,93 mil. | −49,80 % |
Gotovina iz financiranja | 1,18 mil. | −96,14 % |
Neto promjena novca | −265,00 tis. | −114,51 % |
Slobodan tok novca | −9,99 mil. | 64,96 % |
Više
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Glavni izvršni direktor
Osnovano
1990
Web-lokacija
Zaposlenici
154
